A Biomarker Study of STA9090 in Castration-Resistant Prostate Cancer (CRPC) With Assessment of Androgen Receptor Pathway Signaling
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2015
At a glance
- Drugs Ganetespib (Primary) ; Dutasteride
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 01 Dec 2012 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 01 Mar 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 09 Jun 2011 New trial record